THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, January 15, 2020
Inotiv's acquisition of Histion is a strategic move toward expanding its specialist pathology services.
Fremont, CA : “The acquisition of Histion extends our histology operations into highly-specialized plastics and medical device pathology,” comments Greg Beattie, Chief Operating Officer, Discovery and Development Services at Inotiv. Histion, LLC has been acquired by Inotiv, Inc., a leading contract research firm focusing in nonclinical and analytical drug discovery and development services, research models, and related goods and services, with an effective date of April 25, 2022. The acquisition is an important part of the company's strategy to expand its specialist pathology services.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“This acquisition will also support the previously announced expansion of our surgical model and medical device testing services in Fort Collins, CO, and will accelerate the development of these services and our future expansion plans.” adds Beattie.
Beattie continues, “We have a valued, longstanding history of working with Histion, and are confident that the addition of Histions expert team will enable us to better assist our clients in study design and the effective evaluation of the safety and efficacy of medical devices across a very broad array of therapeutic indications.”
"We are thrilled to be part of Inotiv's growth. Integrating our pathology expertise with the comprehensive services at Inotiv will allow us to provide more complete and flexible solutions to our clients." states Peggy Lalor, President and Founder of Histion.
More in News